RxDoctor Payments Data

Latasha Henry, MD

Gastroenterology · Mobile, ALNPI 1326304171

Payments from drug & device makers

$2,572in general payments, 2019–2025

Across 144 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$657
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$344
  • Takeda Pharmaceuticals U.S.A., Inc.$216
  • Covidien LP$185
  • Gilead$134
  • Johnson & Johnson$118
  • plus $919 from 21 others

What the payments were for

  • Food & beverage$2,53999%
  • Education$331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,572 in reported general payments places this provider in the 35th percentile of 225 gastroenterology providers in Alabama.

See all gastroenterology providers in Alabama

Medicare billing

Part B allowed, 2024
$94,075
Medicare patients
336
Services billed
850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntyvioVedolizumab13$110,571
CreonLipase/Protease/Amylase26$41,958
LinzessLinaclotide41$26,158
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates240$14,987
Sucralfate119$10,103
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag42$5,319
Mesalamine34$3,318
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg116$2,762
Pantoprazole Sodium160$2,056
Famotidine117$1,986
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine40$1,706
Omeprazole86$1,532
Lubiprostone21$1,389
Ursodiol14$1,359
Azathioprine28$1,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$216$110,57113 claims
AbbVieCreon, Linzess$657$68,11567 claims
Braintree Laboratories, Inc.Suflave$11$5,31942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 225 gastroenterology providers in Alabama.

Other gastroenterology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →